Tags

Type your tag names separated by a space and hit enter

Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities.
Am J Physiol. 1992 Mar; 262(3 Pt 2):H654-60.AJ

Abstract

The cyclic nucleotide phosphodiesterase (PDE) forms present in frog atrial fibers were isolated and characterized by their drug sensitivities. DEAE-sephacel chromatography of cytosolic PDE activity resolved three major PDE forms: peak A hydrolyzed both adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP) and was activated by calcium-calmodulin (PDE I); peak B also hydrolyzed both cAMP and cGMP but was activated by 5 microM cGMP (PDE II); peak C specifically hydrolyzed cAMP (PDE IV). Rolipram specifically inhibited PDE IV (Ki = 1.1 microM), whereas dipyridamole potently inhibited both PDE II (Ki = 4.6 microM) and PDE IV (Ki = 0.8 microM). Atrial fiber PDE I was preferentially inhibited by zaprinast (Ki = 10 microM). 3-Isobutyl-1-methyl xanthine (IBMX) and theophylline inhibited nonspecifically all three different enzymes. The positive inotropic drug CI 930 only inhibited the different isolated atrial PDE forms at concentrations greater than 200 microM. However, under assay conditions for which PDE IV was specifically inhibited (presence of 100 microM rolipram), an IC50 of 17 microM for CI 930 was observed on the remaining 26% cAMP hydrolytic activity of peak C (which could represent a cGMP-inhibited PDE form: PDE III). The same PDE forms were also found in frog ventricle. The major difference between frog atrial fiber (and ventricular tissue) PDEs and mammalian cardiac PDEs is that the main cytosolic cAMP-specific hydrolytic activity in frog heart is due to PDE IV rather than PDE III. Rolipram, dipyridamole, and zaprinast might be useful tools to investigate the participation of cAMP in frog atrial contraction (unpublished observations).

Authors+Show Affiliations

Lugnier C
Laboratoire de Pharmacologie Cellulaire et Moléculaire, Centre National de la Recherche Scientifique Unité 600, Université Louis Pasteur de Strasbourg, Illkirch, France.
Gauthier C
No affiliation info available
Le Bec A
No affiliation info available
Soustre H
No affiliation info available

MeSH

1-Methyl-3-isobutylxanthine3',5'-Cyclic-AMP Phosphodiesterases3',5'-Cyclic-GMP PhosphodiesterasesAnimalsCalcium ChlorideCalmodulinChromatography, Ion ExchangeCyclic GMPCytosolDipyridamoleHeart AtriaHeart VentriclesKineticsMyocardiumPapaverinePurinonesPyrrolidinonesRana esculentaRana ridibundaRolipramSubstrate SpecificityTheophylline

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

1373036

Citation

Lugnier, C, et al. "Cyclic Nucleotide Phosphodiesterases From Frog Atrial Fibers: Isolation and Drug Sensitivities." The American Journal of Physiology, vol. 262, no. 3 Pt 2, 1992, pp. H654-60.
Lugnier C, Gauthier C, Le Bec A, et al. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities. Am J Physiol. 1992;262(3 Pt 2):H654-60.
Lugnier, C., Gauthier, C., Le Bec, A., & Soustre, H. (1992). Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities. The American Journal of Physiology, 262(3 Pt 2), H654-60.
Lugnier C, et al. Cyclic Nucleotide Phosphodiesterases From Frog Atrial Fibers: Isolation and Drug Sensitivities. Am J Physiol. 1992;262(3 Pt 2):H654-60. PubMed PMID: 1373036.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities. AU - Lugnier,C, AU - Gauthier,C, AU - Le Bec,A, AU - Soustre,H, PY - 1992/3/1/pubmed PY - 1992/3/1/medline PY - 1992/3/1/entrez SP - H654 EP - 60 JF - The American journal of physiology JO - Am J Physiol VL - 262 IS - 3 Pt 2 N2 - The cyclic nucleotide phosphodiesterase (PDE) forms present in frog atrial fibers were isolated and characterized by their drug sensitivities. DEAE-sephacel chromatography of cytosolic PDE activity resolved three major PDE forms: peak A hydrolyzed both adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP) and was activated by calcium-calmodulin (PDE I); peak B also hydrolyzed both cAMP and cGMP but was activated by 5 microM cGMP (PDE II); peak C specifically hydrolyzed cAMP (PDE IV). Rolipram specifically inhibited PDE IV (Ki = 1.1 microM), whereas dipyridamole potently inhibited both PDE II (Ki = 4.6 microM) and PDE IV (Ki = 0.8 microM). Atrial fiber PDE I was preferentially inhibited by zaprinast (Ki = 10 microM). 3-Isobutyl-1-methyl xanthine (IBMX) and theophylline inhibited nonspecifically all three different enzymes. The positive inotropic drug CI 930 only inhibited the different isolated atrial PDE forms at concentrations greater than 200 microM. However, under assay conditions for which PDE IV was specifically inhibited (presence of 100 microM rolipram), an IC50 of 17 microM for CI 930 was observed on the remaining 26% cAMP hydrolytic activity of peak C (which could represent a cGMP-inhibited PDE form: PDE III). The same PDE forms were also found in frog ventricle. The major difference between frog atrial fiber (and ventricular tissue) PDEs and mammalian cardiac PDEs is that the main cytosolic cAMP-specific hydrolytic activity in frog heart is due to PDE IV rather than PDE III. Rolipram, dipyridamole, and zaprinast might be useful tools to investigate the participation of cAMP in frog atrial contraction (unpublished observations). SN - 0002-9513 UR - https://www.unboundmedicine.com/medline/citation/1373036/Cyclic_nucleotide_phosphodiesterases_from_frog_atrial_fibers:_isolation_and_drug_sensitivities_ DB - PRIME DP - Unbound Medicine ER -